Screening for rheumatoid arthritis-associated interstitial lung disease-a Delphi-based consensus statement

Klaus Hackner; Lisa Hütter; Holger Flick; Michael Grohs; Kastriot Kastrati; Hans Kiener; David Lang; Birgit Mosheimer-Feistritzer; Helmut Prosch; Eva Rath; Otmar Schindler; Florentine Moazedi-Fürst

doi:10.1007/s00393-023-01464-w

Screening for rheumatoid arthritis-associated interstitial lung disease-a Delphi-based consensus statement

Klaus Hackner, Lisa Hütter, Holger Flick, Michael Grohs, Kastriot Kastrati, Hans Kiener, David Lang, Birgit Mosheimer-Feistritzer, Helmut Prosch, Eva Rath, Otmar Schindler, Florentine Moazedi-Fürst^*

^*Corresponding author for this work

Division of Pneumology (University Hospital Krems)

Research output: Journal article (peer-reviewed) › Journal article

11 Citations (Scopus)

Abstract

OBJECTIVE: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a major driver of premature mortality in patients with rheumatoid arthritis (RA). Detection of RA-ILD is crucial but requires awareness among the treating physicians. To date, however, there is no international recommendation concerning screening for ILD in RA patients.

METHODS: After a systematic literature review, the modified Delphi technique in combination with the nominal group technique was used to provide a Delphi consensus statement elaborated by an expert panel of pneumonologists, rheumatologists, and a radiologist. Based on the available evidence, several clusters of questions were defined and discussed until consent was reached.

RESULTS: A screening algorithm for ILD in patients with RA based on clinical signs, respiratory symptoms, and risk factors has been developed. Further, the recommendations address diagnostic tools for RA-ILD and the follow-up of RA patients qualifying for ILD screening.

Translated title of the contribution	Screening auf mit rheumatoider Arthritis assoziierte interstitielle Lungenerkrankung – Delphi-basiertes Konsensus-Statement
Original language	English
Pages (from-to)	160-168
Number of pages	9
Journal	Zeitschrift fur Rheumatologie
Volume	83
Issue number	2
Early online date	19 Jan 2024
DOIs	https://doi.org/10.1007/s00393-023-01464-w
Publication status	Published - Mar 2024

Keywords

Antifibrotic agents
Autoimmune diseases
Fibrosis
Mass screening
Risk factors
Arthritis, Rheumatoid/complications
Lung Diseases, Interstitial/diagnosis
Humans
Risk Factors

ASJC Scopus subject areas

Rheumatology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00393-023-01464-w

Cite this

Hackner, K., Hütter, L., Flick, H., Grohs, M., Kastrati, K., Kiener, H., Lang, D., Mosheimer-Feistritzer, B., Prosch, H., Rath, E., Schindler, O., & Moazedi-Fürst, F. (2024). Screening for rheumatoid arthritis-associated interstitial lung disease-a Delphi-based consensus statement. Zeitschrift fur Rheumatologie, 83(2), 160-168. https://doi.org/10.1007/s00393-023-01464-w

@article{db702e05118c4ee79d1144570dc33463,

title = "Screening for rheumatoid arthritis-associated interstitial lung disease-a Delphi-based consensus statement",

abstract = "OBJECTIVE: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a major driver of premature mortality in patients with rheumatoid arthritis (RA). Detection of RA-ILD is crucial but requires awareness among the treating physicians. To date, however, there is no international recommendation concerning screening for ILD in RA patients.METHODS: After a systematic literature review, the modified Delphi technique in combination with the nominal group technique was used to provide a Delphi consensus statement elaborated by an expert panel of pneumonologists, rheumatologists, and a radiologist. Based on the available evidence, several clusters of questions were defined and discussed until consent was reached.RESULTS: A screening algorithm for ILD in patients with RA based on clinical signs, respiratory symptoms, and risk factors has been developed. Further, the recommendations address diagnostic tools for RA-ILD and the follow-up of RA patients qualifying for ILD screening.",

keywords = "Antifibrotic agents, Autoimmune diseases, Fibrosis, Mass screening, Risk factors, Arthritis, Rheumatoid/complications, Lung Diseases, Interstitial/diagnosis, Humans, Risk Factors",

author = "Klaus Hackner and Lisa H{\"u}tter and Holger Flick and Michael Grohs and Kastriot Kastrati and Hans Kiener and David Lang and Birgit Mosheimer-Feistritzer and Helmut Prosch and Eva Rath and Otmar Schindler and Florentine Moazedi-F{\"u}rst",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2024.",

year = "2024",

month = mar,

doi = "10.1007/s00393-023-01464-w",

language = "English",

volume = "83",

pages = "160--168",

journal = "Zeitschrift fur Rheumatologie",

issn = "0340-1855",

publisher = "Springer Medizin",

number = "2",

}

Hackner, K, Hütter, L, Flick, H, Grohs, M, Kastrati, K, Kiener, H, Lang, D, Mosheimer-Feistritzer, B, Prosch, H, Rath, E, Schindler, O & Moazedi-Fürst, F 2024, 'Screening for rheumatoid arthritis-associated interstitial lung disease-a Delphi-based consensus statement', Zeitschrift fur Rheumatologie, vol. 83, no. 2, pp. 160-168. https://doi.org/10.1007/s00393-023-01464-w

TY - JOUR

T1 - Screening for rheumatoid arthritis-associated interstitial lung disease-a Delphi-based consensus statement

AU - Hackner, Klaus

AU - Hütter, Lisa

AU - Flick, Holger

AU - Grohs, Michael

AU - Kastrati, Kastriot

AU - Kiener, Hans

AU - Lang, David

AU - Mosheimer-Feistritzer, Birgit

AU - Prosch, Helmut

AU - Rath, Eva

AU - Schindler, Otmar

AU - Moazedi-Fürst, Florentine

N1 - Publisher Copyright: © The Author(s) 2024.

PY - 2024/3

Y1 - 2024/3

N2 - OBJECTIVE: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a major driver of premature mortality in patients with rheumatoid arthritis (RA). Detection of RA-ILD is crucial but requires awareness among the treating physicians. To date, however, there is no international recommendation concerning screening for ILD in RA patients.METHODS: After a systematic literature review, the modified Delphi technique in combination with the nominal group technique was used to provide a Delphi consensus statement elaborated by an expert panel of pneumonologists, rheumatologists, and a radiologist. Based on the available evidence, several clusters of questions were defined and discussed until consent was reached.RESULTS: A screening algorithm for ILD in patients with RA based on clinical signs, respiratory symptoms, and risk factors has been developed. Further, the recommendations address diagnostic tools for RA-ILD and the follow-up of RA patients qualifying for ILD screening.

AB - OBJECTIVE: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a major driver of premature mortality in patients with rheumatoid arthritis (RA). Detection of RA-ILD is crucial but requires awareness among the treating physicians. To date, however, there is no international recommendation concerning screening for ILD in RA patients.METHODS: After a systematic literature review, the modified Delphi technique in combination with the nominal group technique was used to provide a Delphi consensus statement elaborated by an expert panel of pneumonologists, rheumatologists, and a radiologist. Based on the available evidence, several clusters of questions were defined and discussed until consent was reached.RESULTS: A screening algorithm for ILD in patients with RA based on clinical signs, respiratory symptoms, and risk factors has been developed. Further, the recommendations address diagnostic tools for RA-ILD and the follow-up of RA patients qualifying for ILD screening.

KW - Antifibrotic agents

KW - Autoimmune diseases

KW - Fibrosis

KW - Mass screening

KW - Risk factors

KW - Arthritis, Rheumatoid/complications

KW - Lung Diseases, Interstitial/diagnosis

KW - Humans

KW - Risk Factors

UR - https://www.scopus.com/pages/publications/85182718012

U2 - 10.1007/s00393-023-01464-w

DO - 10.1007/s00393-023-01464-w

M3 - Journal article

C2 - 38240817

SN - 0340-1855

VL - 83

SP - 160

EP - 168

JO - Zeitschrift fur Rheumatologie

JF - Zeitschrift fur Rheumatologie

IS - 2

ER -